Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients With Mixed Hyperlipidemia

Cardiovascular Drugs and Therapy - Netherlands
doi 10.1007/s10557-016-6666-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials

Journal of Pharmacy and Pharmaceutical Sciences
MedicinePharmacologyPharmaceutical Science
2017English

Efficacy and Safety of Monascus Purpureus Went Rice in Subjects With Hyperlipidemia

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2005English

Questioning the Safety and Benefits of Evolocumab

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

Journal of the American Heart Association
Cardiovascular MedicineCardiology
2017English

Clinical Utility of Evolocumab in the Management of Hyperlipidemia: Patient Selection and Follow-Up

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

Non-Interventional Study of Efficacy and Safety of Rosuvastatin Therapy and Introduction of Additional Doses to Clinical Practice in Patients With Hyperlipidemia

Cardiologia Croatica
Cardiovascular MedicineCardiology
2020English

Questioning the Safety and Benefits of Evolocumab – Authors' Reply

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Efficacy of Evolocumab in Monogenic Versus Polygenic Hypercholesterolemia

CJC Open
Cardiovascular MedicineCardiology
2019English

Safety and Efficacy of a Topical Sodium Channel Inhibitor (TV-45070) in Patients With Postherpetic Neuralgia (PHN)

Clinical Journal of Pain
NeurologyAnesthesiologyPain Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy